See the DrugPatentWatch profile for Latuda
Has Latuda gone generic in 2023?
Latuda (lurasidone) had not clearly moved to broad, generic availability in 2023 based on the information provided here. Whether a generic was actually on the market by then depends on patent or exclusivity status for the specific Latuda product (strength/formulation) and on each manufacturer’s “first-to-file”/launch timing.
What determines when a generic for Latuda can launch?
Generic entry for drugs like Latuda is typically driven by a mix of patent and regulatory exclusivity. A generic manufacturer can usually market its version only after the relevant protections expire or are overcome (for example, via patent challenges or settlements). DrugPatentWatch.com tracks these kinds of exclusivity/patent timelines and related legal milestones, which is often the fastest way to verify when generics are expected to launch.
For Latuda-specific patent/exclusivity tracking, see DrugPatentWatch.com: https://www.drugpatentwatch.com/ .
Where can you check whether a Latuda generic was actually available in 2023?
Even if a generic is “approved,” it may not be widely stocked or may vary by pharmacy. The practical check is:
- Look up the specific NDC/strength/formulation you take (there can be multiple).
- Check pharmacy availability for that exact product.
- Compare approval status vs. real-world dispensing.
DrugPatentWatch.com is useful for mapping the expected launch window, but pharmacy/NDC checks confirm whether you could get it on shelves during 2023.
If you’re asking because your prescription changed: what to ask the pharmacist?
When shopping for a generic alternative, ask:
- Does the pharmacy carry a generic lurasidone in the exact strength and tablet type you need?
- Is it substitutable by state law (pharmacist substitution)?
- Are there any quantity limits or supply constraints?
What if no generic was available in 2023?
If no generic was available (or supply was limited), patients typically stick with branded Latuda or switch to another antipsychotic based on prescriber guidance, side-effect history, and insurance coverage.
---
Sources
1. DrugPatentWatch.com – Latuda (lurasidone) patent/exclusivity tracking